NextCure to Present Preclinical Data on NC318, a Novel Immunomedicine Targeting Siglec-15, at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting

Nov. 8, 2018 11:30 UTC

BELTSVILLE, Md.--(BUSINESS WIRE)-- NextCure, Inc.  a privately-held biopharmaceutical company discovering and developing next generation immunomedicines for cancer and other diseases, today announced that preclinical data supporting the development of its lead drug candidate, NC318, will be presented in a poster session at the Society for Immunotherapy of Cancer 33rd Annual Meeting being held November 7th – 11th 2018 in Washington, D.C. NC318 is a humanized monoclonal antibody specific for Siglec-15 (S15), a novel immunomodulatory target found on a restricted set of myeloid cells and on certain tumor types.

The poster will be displayed in the poster hall both Friday, November 9 and Saturday, November 10. Presentation details are provided below:

P678: “Targeting Siglec-15 with NC318, a Novel Therapeutic Antibody to Enhance Anti-Tumor Immunity”

About NC318

NC318 is a first-in-class immunomedicine against a novel immunomodulatory target found on a restricted set of myeloid cells in the tumor microenvironment and on certain tumor types including lung, ovarian and head and neck cancers. Preclinical research shows that S15 promotes the survival and differentiation of suppressive myeloid cells and negatively regulates T cell function, allowing cancer growth. In preclinical studies, NC318 blocks the negative effects of S15. NC318 is a first-in-class immunomedicine that has the potential to treat multiple cancer types.

About NextCure, Inc.

NextCure is a biopharmaceutical company focused on discovering and developing next generation first-in-class immunomedicines for cancer and other diseases. Our novel FIND-IO™ discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. Our initial focus is to bring hope and new treatments to patients who do not respond to current cancer therapies.

NextCure Cautionary Statement Regarding Forward-Looking Statements

Statements made in this press release that are not historical facts are forward-looking statements. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as NextCure’s ability to raise additional capital, and risks related to NextCure’s ability to initiate, and enroll patients in, planned clinical trials. Further, there can be no assurance of the results of any clinical trial with NC318. You should not place undue reliance on any forward-looking statements. NextCure assumes no obligation to update any forward-looking statements.



company contact
NextCure, Inc.
Timothy Mayer, Ph.D., 240-762-6486
VP, Business Operations & Administration
media contact
MacDougall Biomedical Communications
Shai Biran, Ph.D., 781-235-3060


Source: NextCure, Inc.

Back to news